NCT02899104View on ClinicalTrials.gov

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Xofigo (Radium-223 dichloride, BAY88-8223)

Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Trial Locations (1)

07981

Whippany, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY